Hence, these results suggest that targeting LD-Wnt signaling could be beneficial in BRAF-mutated PM-CRC, possibly using AXIN2 expression as a biomarker for treatment selection which is more feasible than finding RNF43/RSPO aberrations through RNA-sequencing. This evidence concerns the gene RNF43 and colorectal carcinoma.